[Movement Interpretation] Daily target 2x long MRNA surged on September 23: melanoma + phase III data + active options

1. On September 23rd, Moderna plans to attend the Bernstein Healthcare Leaders & Disruptors Annual Conference; the company’s personalized neoantigen therapy pipeline continues to be scheduled for data presentations.
2. On September 21st, Moderna announced that phase III data of its personalized mRNA therapy intismeran autogene for post-resection stage IIB to IV melanoma will be released on October 24th during the presidential plenary session at the 2026 ESMO conference. Additionally, three related abstracts will be presented as oral reports.
3. On August 19th, Moderna and Merck announced that the phase III trial of intismeran combined with pembrolizumab for high-risk melanoma reached the primary endpoint of recurrence-free survival as well as the key secondary endpoint of metastasis-free survival, with no new safety risks identified.
4. On September 22nd, Moderna’s options trading volume reached 241,300 contracts, with call options accounting for 66.68% and open interest around 766,100 contracts; MRNX is a daily target 2x long Moderna product, where price volatility of the underlying asset will be amplified by the leverage mechanism.

(Disclaimer: This content is gathered and summarized by AI technology from public information and is for reference only. It does not constitute investment advice.)